AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16024305 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily for 4-8 weeks
Number of subjects: 560
Study 16024305 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily
Number of subjects: 560
Study 16024305 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance with rabeprazole 10 mg or 2x10 mg once daily for a maximum of 48 weeks
Number of subjects: 560
Study 11745525 — intervention group
Group type: EXPERIMENTAL
Intervention: CoStasis surgical hemostat containing bovine thrombin and collagen with the patient's own plasma
Number of subjects: 176
Study 11745525 — intervention group
Group type: COMPARATOR
Intervention: Instat collagen sponge
Number of subjects: 176
Study 9286804 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0
Study 9286804 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 0
Study 9384841 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual discontinuation of lithium
Number of subjects: 0
Study 9384841 — intervention group
Group type: COMPARATOR
Intervention: Abrupt interruption of lithium
Number of subjects: 0
Study 9384841 — intervention group
Group type: COMPARATOR
Intervention: Sharp reduction in lithium dose
Number of subjects: 0
Study 9384841 — intervention group
Group type: COMPARATOR
Intervention: Other disorders and treatments (neuroleptics in schizophrenia, antidepressants in recurrent depression)
Number of subjects: 0
Study 3711599 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat breakfast followed by iv injection of 1000 u heparin (high NEFA protocol)
Number of subjects: 10
Study 3711599 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate breakfast (low NEFA protocol)
Number of subjects: 10
Study 2688971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 594
Study 2688971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594
Study 30862961 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH) at 33.5 °C for 72 h in OC trial
Number of subjects: 572
Study 30862961 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH) at 33.5 °C for 72 h in IH trial
Number of subjects: 572
Study 30862961 — intervention group
Group type: COMPARATOR
Intervention: OC trial (cooling to 33.5 °C for 72 h)
Number of subjects: 572
Study 30862961 — intervention group
Group type: COMPARATOR
Intervention: IH trial
Number of subjects: 572
Study 28635634 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 + 4 g/day oral EAAs
Number of subjects: 112
Study 28635634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 26233286 — intervention group
Group type: EXPERIMENTAL
Intervention: Decorated objects (e.g., polka dots, feathers)
Number of subjects: 67
Study 26233286 — intervention group
Group type: COMPARATOR
Intervention: Plain and monochromatic objects
Number of subjects: 67
Study 23906876 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve replacement (MVR) in group 1 (PAP < 50 mmHg)
Number of subjects: 25
Study 23906876 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve replacement (MVR) in group 2 (PAP ≥ 50 mmHg)
Number of subjects: 25
Study 21210776 — intervention group
Group type: EXPERIMENTAL
Intervention: Berlin-Frankfürt-Münster-derived acute lymphoblastic leukaemia (ALL) therapy
Number of subjects: 53
Study 18241972 — intervention group
Group type: EXPERIMENTAL
Intervention: FAED
Number of subjects: 176
Study 18241972 — intervention group
Group type: COMPARATOR
Intervention: SAED
Number of subjects: 176
Study 17243596 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond (CPB, Kuraray)
Number of subjects: 320
Study 17243596 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐Bond (GBO, GC)
Number of subjects: 320
Study 17243596 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Bond (HYB, Sun Medical)
Number of subjects: 320
Study 17243596 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond NG experimental (ING, Heraeus Kulzer)
Number of subjects: 320
Study 17243596 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond (TSB, Kuraray)
Number of subjects: 320
Study 15504183 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.03 mg kg(‐1)
Number of subjects: 120
Study 15504183 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 120
Study 11549539 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (250 mg of vitamin C, 50 IU of alpha-tocopherol, and 12 oz of vegetable cocktail daily for 2 weeks)
Number of subjects: 31
Study 11549539 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 31
Study 11549539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9029389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin administered preoperatively (1 g)
Number of subjects: 90
Study 9029389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin administered after cord clamping (1 g)
Number of subjects: 90
Study 8299661 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg once a day
Number of subjects: 30
Study 8299661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3571079 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training group (n = 40)
Number of subjects: 89
Study 3571079 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 49)
Number of subjects: 89
Study 3571079 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study 30548375 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Reflection and Insight Therapy (MERIT)
Number of subjects: 14
Study 30548375 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for psychosis (CBTp) or Metacognition‐Oriented Social Skills training
Number of subjects: 14
Study 30554366 — intervention group
Group type: COMPARATOR
Intervention: Control treatment based on P. purpureum (PT) grass
Number of subjects: 7
Study 30554366 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomillspaughia emargiata (NE)
Number of subjects: 7
Study 30554366 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabernaemontana amygdalifolia (TA)
Number of subjects: 7
Study 30554366 — intervention group
Group type: EXPERIMENTAL
Intervention: Caesalpinia gaumeri (CG)
Number of subjects: 7
Study 30554366 — intervention group
Group type: EXPERIMENTAL
Intervention: Piscidia piscipula (PP)
Number of subjects: 7
Study 30554366 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucaena leucocephala (LL)
Number of subjects: 7
Study 30554366 — intervention group
Group type: EXPERIMENTAL
Intervention: Havardia albicans (HA)
Number of subjects: 7
Study 28343108 — intervention group
Group type: EXPERIMENTAL
Intervention: mTG-modified wheat flour rusks (n=11)
Number of subjects: 21
Study 28343108 — intervention group
Group type: COMPARATOR
Intervention: Unmodified wheat flour rusks (n=10)
Number of subjects: 21
Study 25241089 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium w (Mw)
Number of subjects: 50
Study 25241089 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 24287222 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar strap
Number of subjects: 140
Study 24287222 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports tape
Number of subjects: 140
Study 24287222 — intervention group
Group type: COMPARATOR
Intervention: Placebo tape
Number of subjects: 140
Study 24287222 — intervention group
Group type: COMPARATOR
Intervention: No orthosis
Number of subjects: 140
Study 21689982 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 28
Study 21689982 — intervention group
Group type: COMPARATOR
Intervention: Non-obstructive sleep apnea (non-OSA)
Number of subjects: 28
Study 18516532 — intervention group
Group type: EXPERIMENTAL
Intervention: PJ with an internal stent (group I)
Number of subjects: 43
Study 18516532 — intervention group
Group type: COMPARATOR
Intervention: PJ with an external stent (group E)
Number of subjects: 43
Study 16496307 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (3 g, intravenously, n = 15)
Number of subjects: 37
Study 16496307 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 37
Study 12492803 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. remifentanil (1.5 micro g kg‐1, followed by 0.2 micro g kg‐1 min‐1)
Number of subjects: 50
Study 12492803 — intervention group
Group type: COMPARATOR
Intervention: i.v. sufentanil (0.2 micro g kg‐1 followed by 0.2 micro g kg‐1 h‐1)
Number of subjects: 50
Study 12492803 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil
Number of subjects: 50
Study 12492803 — intervention group
Group type: COMPARATOR
Intervention: sufentanil
Number of subjects: 50
Study 11736778 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of ropivacaine 0.1% and sufentanil 1 microg x ml(‐1) at a rate of 5‐9 ml x h(‐1)
Number of subjects: 24
Study 11736778 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient‐controlled analgesia using piritramide
Number of subjects: 24
Study 11736778 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of ropivacaine 0.1% and sufentanil 1 microg x ml(‐1)
Number of subjects: 24
Study 9249623 — intervention group
Group type: EXPERIMENTAL
Intervention: EBD students
Number of subjects: 81
Study 9249623 — intervention group
Group type: COMPARATOR
Intervention: Learning disabilities students
Number of subjects: 81
Study 9249623 — intervention group
Group type: COMPARATOR
Intervention: Problem children (PC)
Number of subjects: 81
Study 9249623 — intervention group
Group type: COMPARATOR
Intervention: Normal children (NC)
Number of subjects: 81
Study 8308771 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interferon-gamma (rIFN-gamma)
Number of subjects: 70
Study 2879458 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of ipratropium bromide
Number of subjects: 199
Study 2879458 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg of fenoterol hydrobromide
Number of subjects: 199
Study 2879458 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of ipratropium plus 1.25 mg of fenoterol
Number of subjects: 199
Study 2879458 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 199
Study 31757776 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-esteem intervention (7 weekly sessions in Second Life)
Number of subjects: 21
Study 31757776 — intervention group
Group type: COMPARATOR
Intervention: Control group (received intervention materials at the end of the study)
Number of subjects: 21
Study 30893450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI)
Number of subjects: 0
Study 30893450 — intervention group
Group type: COMPARATOR
Intervention: Laser control
Number of subjects: 0
Study 28619115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - 120 min/week walking (396 METs/min/week) and monthly sociocultural gatherings
Number of subjects: 364
Study 28619115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 364
Study 25553559 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted seated position
Number of subjects: 12
Study 25553559 — intervention group
Group type: COMPARATOR
Intervention: Upright seated position
Number of subjects: 12
Study 22878057 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal dartos flap rotation
Number of subjects: 17
Study 22878057 — intervention group
Group type: COMPARATOR
Intervention: Suturing tunica albuginea to the pubic periosteum
Number of subjects: 17
Study 20980335 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µM trabedersen
Number of subjects: 145
Study 20980335 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 µM trabedersen
Number of subjects: 145
Study 20980335 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (temozolomide or procarbazine/lomustine/vincristine)
Number of subjects: 145
Study 20980335 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 145
Study 18321354 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized group CBT
Number of subjects: 178
Study 18321354 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual CBT
Number of subjects: 178
Study 16582025 — intervention group
Group type: EXPERIMENTAL
Intervention: KRG-rootlets (6 g)
Number of subjects: 19
Study 16582025 — intervention group
Group type: EXPERIMENTAL
Intervention: KRG-rootlets (mean of 3 doses)
Number of subjects: 19
Study 16582025 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 g)
Number of subjects: 19
Study 14527076 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 0
Study 14527076 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 10780123 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch (21 mg)
Number of subjects: 61
Study 10780123 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 61
Study 8798245 — intervention group
Group type: COMPARATOR
Intervention: Total homocysteine (tHcy) levels in children whose father, grandfather, or uncle died at age ≤ 55 years of myocardial infarction or sudden cardiac arrest (n = 42)
Number of subjects: 756
Study 8798245 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum folate, plasma creatinine, and sugar intake as percent of dietary energy
Number of subjects: 756
Study 2001315 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilisation splint (SS)
Number of subjects: 68
Study 2001315 — intervention group
Group type: EXPERIMENTAL
Intervention: Localised occlusal interference splint (LOIS)
Number of subjects: 68
Study 6132630 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual lorazepam
Number of subjects: 12
Study 6132630 — intervention group
Group type: COMPARATOR
Intervention: Oral lorazepam
Number of subjects: 12
Study 31350122 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (6 weeks treatment)
Number of subjects: 0
Study 31350122 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 weeks treatment)
Number of subjects: 0
Study 29098250 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA apical barrier technique
Number of subjects: 75
Study 29098250 — intervention group
Group type: COMPARATOR
Intervention: Vitapex apexification
Number of subjects: 75
Study 26519693 — intervention group
Group type: EXPERIMENTAL
Intervention: High cut-off dialysis
Number of subjects: 43
Study 26519693 — intervention group
Group type: COMPARATOR
Intervention: High-flux dialysis
Number of subjects: 43
Study 23254732 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone cyclophosphamide pulse (DCP) therapy
Number of subjects: 19
Study 23254732 — intervention group
Group type: COMPARATOR
Intervention: Oral cyclophosphamide
Number of subjects: 19
Study 20444947 — intervention group
Group type: EXPERIMENTAL
Intervention: Correctional boot camp
Number of subjects: 0
Study 20444947 — intervention group
Group type: COMPARATOR
Intervention: Traditional prison
Number of subjects: 0
Study 19064982 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg/d for 4 weeks, 2 weeks off)
Number of subjects: 23
Study 17724176 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin
Number of subjects: 45
Study 17724176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 15483340 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic pharyngometry in four body positions (sitting, supine, right and left lateral) while awake with tidal breathing
Number of subjects: 70
Study 15483340 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic pharyngometry
Number of subjects: 70
Study 15483340 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG)
Number of subjects: 70
Study 11505259 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid fixation (n = 78)
Number of subjects: 127
Study 11505259 — intervention group
Group type: COMPARATOR
Intervention: Wire fixation (n = 49)
Number of subjects: 127
Study 11505259 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid fixation with genioplasty (n = 35)
Number of subjects: 127
Study 11505259 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire fixation with genioplasty (n = 24)
Number of subjects: 127
Study 9611933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavity wall finish with regular cavosurface angle
Number of subjects: 0
Study 9611933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavity wall finish with non-standard cavosurface angle
Number of subjects: 0
Study 8813779 — intervention group
Group type: EXPERIMENTAL
Intervention: French technique
Number of subjects: 49
Study 8813779 — intervention group
Group type: COMPARATOR
Intervention: American technique
Number of subjects: 49
Study 2286465 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (3 g)
Number of subjects: 562
Study 2286465 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (200 mg)
Number of subjects: 562
Study 2286465 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (1.92 g)
Number of subjects: 562
Study 7240438 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (3.25 Gm/day)
Number of subjects: 12
Study 7240438 — intervention group
Group type: COMPARATOR
Intervention: Naproxen sodium (1.1 Gm/day)
Number of subjects: 12
Study 30643596 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation training (SIM)
Number of subjects: 70
Study 30643596 — intervention group
Group type: COMPARATOR
Intervention: Low-fidelity CPR manikin training (STD)
Number of subjects: 70
Study 27918854 — intervention group
Group type: EXPERIMENTAL
Intervention: High EF (8 eating occasions/day)
Number of subjects: 15
Study 27918854 — intervention group
Group type: COMPARATOR
Intervention: Low EF (3 eating occasions/day)
Number of subjects: 15
Study 27053264 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit-based education (ABE)
Number of subjects: 4
Study 27053264 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines and prompts (G&P)
Number of subjects: 4
Study 25462140 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz right temporoparietal rTMS for 17 minutes
Number of subjects: 24
Study 25462140 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 24
Study 22001361 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based communication and support intervention
Number of subjects: 313
Study 19965822 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (IVB) alone
Number of subjects: 85
Study 19965822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) plus low fluence photodynamic therapy (PDT)
Number of subjects: 85
Study 19965822 — intervention group
Group type: COMPARATOR
Intervention: Comparison of IVB alone vs IVB plus low fluence PDT
Number of subjects: 85
Study 17324010 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranpirnase plus doxorubicin
Number of subjects: 360
Study 17324010 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin alone
Number of subjects: 360
Study 16062094 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (4 mg/day)
Number of subjects: 38
Study 16062094 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (400 mg/day)
Number of subjects: 38
Study 16062094 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine (12.5 mg/day)
Number of subjects: 38
Study 16062094 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 38
Study 16062094 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 38
Study 16062094 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine
Number of subjects: 38
Study 11853004 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan 120 mg/m2 on days 1 + 15 plus mitomycin C 8 mg/m2 on day 1
Number of subjects: 64
Study 11853004 — intervention group
Group type: COMPARATOR
Intervention: Oxaliplatin 85 mg/m2 on days 1 + 15 plus mitomycin C 8 mg/m2 on day 1
Number of subjects: 64
Study 9022109 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 14
Study 9022109 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study 7957830 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (800 micrograms.day‐1) for 4 weeks
Number of subjects: 27
Study 7957830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 3109060 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose heparin (5000 IU twice daily)
Number of subjects: 40
Study 3109060 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 40
Study 31307842 — intervention group
Group type: EXPERIMENTAL
Intervention: HD + açaí
Number of subjects: 69
Study 31307842 — intervention group
Group type: COMPARATOR
Intervention: HD + placebo
Number of subjects: 69
Study 29043496 — intervention group
Group type: EXPERIMENTAL
Intervention: erlotinib plus bevacizumab
Number of subjects: 152
Study 29043496 — intervention group
Group type: COMPARATOR
Intervention: erlotinib
Number of subjects: 152
Study 26552503 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg
Number of subjects: 76
Study 26552503 — intervention group
Group type: COMPARATOR
Intervention: Thienopyridine (prasugrel 60 mg or clopidogrel 600 mg)
Number of subjects: 76
Study 25060833 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment program (MTP)
Number of subjects: 135
Study 25060833 — intervention group
Group type: COMPARATOR
Intervention: Community care (treatment-as-usual, TAU)
Number of subjects: 135
Study 21941361 — intervention group
Group type: EXPERIMENTAL
Intervention: Posturing group (face down for 10 days)
Number of subjects: 30
Study 21941361 — intervention group
Group type: COMPARATOR
Intervention: Non-posturing group (avoid face-up position only)
Number of subjects: 30
Study 18353909 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel school-based intervention; specific details on dosage and duration not available.
Number of subjects: 0
Study 18713888 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 3 microg/mL
Number of subjects: 60
Study 18713888 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 4.5 microg/mL
Number of subjects: 60
Study 18713888 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 6 microg/mL
Number of subjects: 60